Use Of Umbilical Cord Matrix Cells

• US 20080299090A1
• Filed: 03/21/2008
• Published: 12/04/2008
• Est. Priority Date: 02/25/2002
• Status: Abandoned Application

• Current Assignee: Kansas State University Research Foundation
• Original Assignee: Cognate BioServices, Inc., Kansas State University Research Foundation
• Inventors: McIntosh, Kevin R., Weiss, Mark, Medicetty, Satish, Vanderwerff, Irene, Anderson, Cameron, Weiss, Rita
• Application Number:
  US12/053,167
• Publication Number:
  US 20080299090A1
• Time in Patent Office: Days
• US Class Current: 424/93.7
• CPC Class Codes: A61K 2035/122 for inducing tolerance or supression of immune responses
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: C12N 5/0605 Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly

Abstract

The invention relates to the isolation and use of stem cells from amniote species (potentially any animal with an umbilical cord, including humans). More particularly the invention relates to obtaining stem cells that are at least multipotent and may be totipotent or nearly totipotent and are envisaged to have a variety of end uses. The cells of the present invention are immunosuppressive and may be used to inhibit the immune response in a subject.

Claims

1. A method comprising administering umbilical cord matrix stem cells to a subject under conditions such that an immune response in said subject is suppressed.

2. The method of claim 1, wherein said umbilical cord matrix stem cells have been previously isolated from said subject.

3. The method of claim 1, wherein said umbilical cord matrix stem cells have been stored in a bank of umbilical cord stem cells.

4. The method of claim 1, wherein said subject is a human.

5. The method of claim 1, wherein said subject has or is at risk of having graft versus host disease.

6. The method of claim 1, wherein said subject has or is suspected of suffering from myocardial ischemia.

7. The method of claim 1, wherein said subject has an autoimmune disease.

8. The method of claim 1, wherein said umbilical cord stem cells are administered intravenously.

9. A method comprising administering a therapeutically effective amount of umbilical cord matrix stem cells to a subject under conditions such that an immune response in said subject is suppressed.

10. The method of claim 9, wherein said umbilical cord matrix stem cells have been previously isolated from said subject.

11. The method of claim 9, wherein said umbilical cord matrix stem cells have been stored in a bank of umbilical cord stem cells.

12. The method of claim 9, wherein said subject is a human.

13. A pharmaceutical preparation comprising:

a therapeutically effective amount of umbilical cord matrix stem cells and pharmaceutically acceptable carrier.

14. The pharmaceutical preparation of claim 13, wherein said therapeutically effective amount is an amount of umbilical cord matrix stem cells sufficient to suppress an immune response in a subject.